Prima BioMed Progresses Japanese Collaboration
December 11, 2015 07:00 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Dec 11, 2015) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) today announces important progress in its collaboration with NEC Corporation and Yamaguchi University in...
Prima BioMed Unveils Phase I Combination Study of IMP321 + Checkpoint Inhibitor
November 18, 2015 07:00 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - Nov 18, 2015) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
Highlights
Prima to run a Phase I safety and dose finding study of...
Prima BioMed Raises A$2.0 Million Through Placement to Leading Australian Institution
October 30, 2015 07:00 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - Oct 30, 2015) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD), a leading immuno-oncology company, announces that it has raised A$2.0 million via an equity placement at...
Prima BioMed Gains Belgian Regulatory Approval to Commence a Registration Phase IIb Study of IMP321
October 27, 2015 07:00 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - Oct 27, 2015) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
Belgium's Federal Agency for Medicines and Health Products Approved the...
Prima BioMed Raises A$1.55M Through Placement to Sophisticated European Healthcare Investor
October 13, 2015 07:00 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - Oct 13, 2015) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company"), a leading immuno-oncology company, announces that it has raised EUR 1M...
Prima BioMed to Present at LEERINK Partners Rare Disease Roundtable
September 25, 2015 07:00 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Sep 25, 2015) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company"), a leading immuno-oncology company, announces that Marc Voigt, CEO, will...
Prima Biomed Announces Commencement of Milestones for IMP701 Program
August 14, 2015 07:00 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - Aug 14, 2015) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") today announced it will receive an undisclosed clinical milestone payment...
Prima BioMed Receives Positive Scientific Advice From the European Medicines Agency for Its Lead Product, IMP321
July 07, 2015 07:00 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Jul 7, 2015) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company"), a leading immuno-oncology company, is pleased to announce that it has received...
Prima BioMed Receives a Research Tax Credit Cash Rebate in France
June 11, 2015 07:00 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Jun 11, 2015) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company"), a leading immuno-oncology company, is pleased to announce that it has...
Prima BioMed to Maintain NASDAQ Listing
June 04, 2015 07:00 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Jun 4, 2015) - Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima", the "Company"), announces that, further to the announcement made on 29 December 2014, it has...